Treatment of Ulcerative Colitis with Camostat Mesilate, A Serine Protease Inhibitor.
スポンサーリンク
概要
- 論文の詳細を見る
We were able to induce and maintain remission with camostat mesilate, a serine protease inhibitor, in two patients with ulcerative colitis, to whom salicylazosulfapyridine could not be administered due to previous side effects. The enzymatic activity of proteases from granulocyte, pancreatic juice and bacteria is possibly harmful to the inflammed colonic mucosa. Camostat mesilate can be expected to have an anti-inflammatory effect on the damaged mucosa of inflammatory bowel disease.(Internal Medicine 32: 350-354, 1993)
- 社団法人 日本内科学会の論文
著者
-
FUJIYAMA Yoshihide
the Second Department of Internal Medicine, Shiga University of Medical Science
-
BAMBA Tadao
the Second Department of Internal Medicine, Shiga University of Medical Science
-
FUJIYAMA Yoshihide
the Second Department of Internal Medicine, Shiga University of Medical Science Hospital
-
BAMBA Tadao
the Second Department of Internal Medicine, Shiga University of Medical Science Hospital
-
SENDA Shigeru
the Second Department of Internal Medicine, Shiga University of Medical Science Hospital
-
HOSODA Shiro
the Second Department of Internal Medicine, Shiga University of Medical Science Hospital
関連論文
- Thalassemia Incidentally Found by Marked Erythrocytosis Due to an Ochre Mutation at Codon 35 in a Japanese Man
- Meningitis Carcinomatosa Originating from an Alpha Fetoprotein-producing Gastric Cancer
- Treatment of Ulcerative Colitis with Camostat Mesilate, A Serine Protease Inhibitor.